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Abstract
Background: Recruitment is a major challenge for many trials; just over half reach their targets and almost a third
resort to grant extensions. The economic and societal implications of this shortcoming are significant. Yet, we have
a limited understanding of the processes that increase the probability that recruitment targets will be achieved.
Accordingly, there is an urgent need to bring analytical rigour to the task of improving recruitment, thereby
increasing the likelihood that trials reach their recruitment targets. This paper presents a conceptual framework that
can be used to improve recruitment to clinical trials.
Methods: Using a case-study approach, we reviewed the range of initiatives that had been undertaken to improve
recruitment in the txt2stop trial using qualitative (semi-structured interviews with the principal investigator) and
quantitative (recruitment) data analysis. Later, the txt2stop recruitment practices were compared to a previous
model of marketing a trial and to key constructs in social marketing theory.
Results: Post hoc, we developed a recruitment optimisation model to serve as a conceptual framework to improve
recruitment to clinical trials. A core premise of the model is that improving recruitment needs to be an iterative,
learning process. The model describes three essential activities: i) recruitment phase monitoring, ii) marketing
research, and iii) the evaluation of current performance. We describe the initiatives undertaken by the txt2stop trial
and the results achieved, as an example of the use of the model.
Conclusions: Further research should explore the impact of adopting the recruitment optimisation model when
applied to other trials.
Keywords: Marketing mix, Marketing model, Recruitment performance, Social marketing, Turnaround, Txt2stop
“Marketing is a learning game. You make a decision.
You watch the results. You learn from the results.
Then you make better decisions”.
Philip Kotler
Background
Randomised controlled trials are the gold standard for
assessing health care interventions as they provide the
most powerful research method for minimising bias [1].
Under-recruitment reduces trial power and results in
imprecise trial effect estimates [2]. This can lead to a
failure in detecting modest but significant clinical bene-
fits. Recruitment remains a major challenge for many
trials [3] as highlighted by McDonald et al. [1], who
studied recruitment to multicentre trials between 1994
and 2002. They reported that only 31% achieved their
original recruitment targets and 53% requested grant
extensions. More recently Sully et al. [4] found that re-
cruitment has improved, but about 45% of trials still
struggle to recruit their sample size and approximately
a third are forced to resort to grant extensions. It re-
mains unclear why some trials succeed while others fail
as the inter-relationship between trial characteristics
and successful recruitment is complex [5]. The UK’s
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Medical Research Council has recognised that failure
to recruit can be attributed to an inability to resolve
practical problems rather than to scientific or trial de-
sign issues [6]. In order to improve recruitment rates
there have been calls to apply greater analytical rigour
and more insightful management practices [7] includ-
ing the suggestion that the performance of clinical tri-
als could be improved by looking beyond the world of
clinical practice, specifically, by using marketing prin-
ciples [7-9].
Marketing and trials
Barriers to participation in trials begin with the kind of
commitment that is required. Participants must com-
mit to following a set of procedures, often involving
additional effort and expense but without the assur-
ance of receiving any direct benefits. Further, commu-
nication can be a barrier as participants can have
difficulties comprehending the meaning of terms such
as randomisation and equipoise [10]; such barriers can
make trial participation seem unattractive. Marketing,
as a discipline, focuses on meeting customers’ needs
through the deep understanding of the factors that in-
fluence purchasing or sign-up decisions (in this case
trial participation). Social marketing is the application
of marketing principles for social benefit [11] and has
been used in public health for more than 30 years, but
mainly to improve promotional or communications ac-
tivities [12,13]. The potential for marketing constructs
to be used to improve the management of clinical trials
remains largely unexplored, although Francis et al. [9]
have suggested the use of marketing models and tech-
niques beneficial for trialists and which can be under-
stood as a five-stage process (Figure 1).
For those managing a trial, it can be valuable to have
a mental model of the required marketing stages. Yet,
while it is useful to know the necessary steps to mar-
keting a trial, this is different from understanding the
range of activities needed to optimise recruitment.
The task of improving recruitment needs to be an it-
erative learning process [14-17] and no guiding theor-
etical framework is available to assist this process of
targeted learning.
Background to txt2stop
Our case study was txt2stop, a single blinded, rando-
mised, control behaviour change trial that sought to es-
tablish the effects of supportive text messages on the
rate of smoking cessation [18]. The trial was scheduled
to recruit 5,800 participants over a 2-year period. Eight
months into the trial, the number of participants that
were randomised was 22% below target. At such a rate,
recruitment would have been completed two years be-
hind schedule and the costs would have exceeded the
budget. However, the trial management team were able
to identify and address the problems affecting recruit-
ment and complete the trial four months early. This
turnaround provides a valuable case that informed the
development of the recruitment optimisation model.
Study purpose
We aimed to generate a new, or to refine an existing
trials-orientated marketing framework, based on the
analysis of the txt2stop case and relevant literature from
social marketing and clinical trials, that can be used by
other trialists to improve recruitment.
Methods
Research methodology
The Francis et al. five-stage model [9] (Figure 1 and
Table 1) was the conceptual framework of reference.
Txt2stop recruitment processes were compared against
the model and these insights were supplemented with a
literature study of social marketing theory by LG. Stud-
ies were sought using academic databases. Emerald,
Web of Science (Web of knowledge), Science Direct,
PsychINFO, PubMed, BioMedCentral, Cochrane Library,
and the internet (Google Scholar), were searched using
the keywords: “social marketing”, “marketing clinical trials”,
and “trial recruitment” for the time period 1960 to 2011.
LG conducted a semi-structured interview with the
principal investigator (CF) obtaining detailed informa-
tion on the measures adopted to improve recruitment.
A semi-structured approach to interviewing allowed
new concepts to emerge from the interview. Notes
were taken during the interview. Additionally, trial
Stage 1 Stage 2 Stage 3 Stage 4 Stage 5
Figure 1 Five stages in marketing a trial.
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documents (promotional and communication material)
and recruitment process data were reviewed.
Results
The model – “Old versus New” and its key marketing
concepts
The recruitment optimisation model is more dynamic than
Francis et al.’s approach as it uses a Kolb-style framework
in which multiple learning events take place as emergent
and on-going processes that are grounded in experience
[19]. The importance of dynamic learning capability was
identified from an analysis of data, especially that from the
semi-structured interview with the principal investigator
(CF) whose description of the measures adopted by
txt2stop was consistent with a Kolbian learning cycle
(Figure 2). The trial’s current recruitment performance
(successes and difficulties) was assessed through data
collection practices (providing concrete experience). Per-
formance data was compared against the trial’s goals and
benchmarks (resulting in reflective observation). Social
marketing constructs and insights from the clinical trial
literature aided the process of sense-making (abstract
conceptualisation). New or improved interventions and
strategies were developed from a deeper understanding,
and then tested and implemented (active experimenta-
tion). The outcomes from these initiatives provided fur-
ther data that started a new learning cycle. Hence, as can
be seen in Figure 3, the recruitment optimisation model is
spiral and not linear, where feedback loops drive improve-
ments in strategies and practices. The recruitment opti-
misation model focuses on the importance of managing
this learning process by adopting appropriate behaviours
for each of Kolb’s stages of the learning cycle.
The Francis model [9] (Figure 1) emphasised the im-
portance of developing deep market knowledge and
redirecting strategy in the light of experience, but did
not describe the range of activities that would ensure ad-
equate knowledge is developed. Drawing on key con-
cepts from the social marketing literature [12,13,20-23]
as well as the txt2stop experience, we found that learn-
ing involves four main tasks:
1. Recruitment phase monitoring
2. Marketing research
3. Performance evaluation
4. Change implementation
Table 1 Activities within the five stages in marketing a trial
Stage Marketing purposes
Set-up 1. To gain the buy-in of the necessary authorities and stakeholders.
2. To gain the buy-in of opinion leaders whose explicit approval provides legitimacy and prestige for the trial.
3. To construct a marketing function within the trial and devise robust systems for ensuring that the marketing (and later sales)
activities are undertaken efficiently, effectively, and in accordance with the values and goals of the trial.
Market
planning
1. To identify and describe the distinctive features of the ‘segments’ of the ‘market’ to be targeted.
2. To discover what people in each of the selected market segments value (i.e., what would encourage them to ‘sign-up’).
3. To develop a ‘value proposition’ (or more than one if required) that can be tested with each of the targeted segments.
4. To enrol the whole trial organisation in working within the trial’s ‘marketing brief’.
Signalling 1. To convey, fully and persuasively, the ‘value proposition’ to sufficient numbers of people in the target market.
2. To convey, fully and persuasively, the ‘value proposition’ to intermediaries (e.g., doctors or nurses), influencing bodies (e.g., ethics
committees), and other agents that can either help or hinder the conduct of the trial.
Learning 1. To learn, through doing, about ‘the market’.
2. To utilise ongoing learning to develop more effective policies and practices.
3. To evaluate and redirect the strategy of a trial as learning is acquired.
Reinforcing 1. To maintain momentum by renewing or upgrading ‘the offer’ made to participants.
2. To sustain commitment of interested parties and other agencies whose support will be needed.
Figure 2 Authors’ representation of the Kolb learning spiral.
Galli et al. Trials 2014, 15:182 Page 3 of 12
http://www.trialsjournal.com/content/15/1/182
The four tasks are interdependent and when combined
they enable trialists to better evaluate recruitment perform-
ance, to identify and understand recruitment problems and
opportunities for improvement, and to successfully im-
plement change initiatives that improve recruitment
rates. Each task is described in turn, with examples from
txt2stop to provide practical illustrations that explain
the concepts.
TASK 1 – recruitment phase monitoring
Trials have several recruitment phases that participants
must progress through to be randomised. The concept is
mentioned by Dyas et al. [15] who argue that recruit-
ment should be considered in two distinct phases: i) get-
ting potential participants to contact the trial and ii)
converting contacts into consents. Within each phase
there can be a number of steps. For instance, in the case
of txt2stop, phase two had two steps.
! Step One: determining via phone, the eligibility of
participants who had previously expressed an
interest in the trial.
! Step Two: obtaining eligible participants’ consent
via SMS.
It was found that the tracking of participants’ progress
within and between phases was essential to allow any
bottlenecks in recruitment to be identified.
TASK 2 – marketing research
Marketing research assists trialists to identify market
segments (categories of prospective participants), resulting
in a greater understanding of their distinctive characteris-
tics. This enables trialists to devise segment-specific strat-
egies that are focused on the specific needs and wants of
each category. Segments can be defined as homogenous
sub-sets of a market, comprised of people who share similar
wants and needs [13].
Marketing research provides a disciplined tool-kit for de-
vising tailored solutions, by ascertaining if the ways in
which the trial is being sold satisfies the specific needs and
wants of each target market segment. This analysis can be
complex as a trial’s target market may consist of several
segments, to whom trial participation needs to be sold. A
trial may need to be sold to trial participants themselves, as
with txt2stop, or in other cases, to their legal representa-
tives [24]. Further, market analysis is used to provide in-
sights into other stakeholders whose involvement can be
vital to a trial’s effectiveness, including its promotion.
Figure 3 The previous five-stage model and the recruitment optimisation model.
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Stakeholders include trial facilitators, intermediaries/col-
laborators, gatekeepers, etc. This was true for txt2stop
whose stakeholders (GPs, pharmacists, and smoking ces-
sation services) were involved in the trial’s promotional ef-
forts [18].
The 7 Ps of the marketing-mix for trial participation
The marketing mix is the framework used for gaining a
detailed understanding of the target market’s attitudes
towards the trial. It is the “the group of variables that a
marketer can alter to successfully sell a product (good or
service)” ([20], p. 189). A marketing mix analysis will need
to be undertaken separately for each market segment.
The marketing mix has seven components (the 7 Ps):
product, price, place (distribution), promotion/communica-
tion, people, processes, and physical environment. Product,
price, place, processes, people, and physical environment
shape the value proposition (the benefits that a trial has to
offer) whereas promotion/communication determines how
a value proposition is communicated. The 7 Ps provide a
format in which systematic learning can occur, aiding tria-
lists’ understanding of what is (or is not) happening and of
what can be done to improve their trial’s appeal. We will
describe each component and then discuss the marketing
research methods that can be applied to gain insights about
the 7 Ps. Table 2 illustrates how each P applied to txt2stop.
Product
The product is the trial itself, participants need to be
“sold” trial participation and are interested in benefits and
not mere attributes. A product (trial) can be conceived on
three levels: core, tangible (actual), and augmented [21].
Understanding the three levels assists in the development
of a marketing strategy.
The core product is the benefits participants are really
buying into [22]. One could also think of trial participation
in general as a core product, in as far as it can provide par-
ticipants with a sense of pride and self-worth for con-
tributing to a good cause – research. One can therefore
distinguish between trial-specific and general core benefits.
Appealing only to the general core benefits may not be
enough to motivate trial participation. People are motivated
by a desire to help others but this is often conditional on
perceiving some personal benefit or at least no significant
disadvantage to the self (conditional altruism) [25].
The tangible product is the actual product or service,
including its features, quality, and brand. The aug-
mented product is the add-on extras; tangible objects or
services that support trial participation. These related
benefits increase the attractiveness of trial participation,
by improving the overall quality of the trial experience.
Price (costs)
Price refers to more than financial cost; it is what partic-
ipants must give up to partake in a trial. There are direct
costs associated with joining a trial (entry costs), largely
covered by the clinical trials literature under barriers to
participation and can include psychological, physical,
time, inconvenience, and monetary costs [2,25-27]. Not
all perceived costs may be real, as they are based on par-
ticipant misconceptions about clinical trials.
Promotion and communication
Promotion covers the activities used to signal the merits of
the other six components of the marketing mix. Effective
Table 2 Txt2stop examples for the 7 Ps
The 7 Ps Examples from txt2stop
Product Core trial specific: Direct and indirect benefits to quitting smoking.
Core general: Feelings of pride and self-worth for contributing to research and the social good.
Tangible: Txt2stop offered the only mobile phone-based smoking cessation support intervention available at the time;
systematic individualised support for time-scarce smokers who value convenience and anonymity. The txt2stop and London
School of Hygiene and Tropical Medicine name and logo were part of the branding, conveying values of scientific integrity.
Augmented: Txt2stop offered a free phone line to answer queries.
Price (costs) Psychological and inconvenience: Concerns about the trial being a ‘scam’ and the possibility of having to provide a saliva
sample.
Promotion/
communication
Mass media: Posters, newspapers and radio adverts, YouTube video, internet banner, and Facebook page. Interpersonal
channels: GPs, pharmacists, and smoking cessation services.
Place Wherever the participant took his/her phone.
People Phone staff were selected on the basis of their communication skills, knowledge of trial procedures, and the ability to
communicate empathy.
Physical environment Not applicable – txt2stop provided its service via mobiles and recruited over the phone. Participants had on the most part
no physical contact with the London School of Hygiene and Tropical Medicine, where the trial was based. A minority
visited the school to provide a saliva sample.
Process Txt2stop streamlined its processes by registering and randomising over the phone, keeping the duration of calls to a
minimum and allowing consent by SMS.
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signalling requires an appropriate message content, framing
of messages, choice of channels, and mode of communi-
cationa [3,23,28,29]. Various media can be used, but
each medium has its strengths and weaknesses. One must
consider the costs, size, and type of audiences reached by
each type of medium and determine the suitability of the
vehicle for the message content and target audience [22].
Effective communication requires educating participants
about the trial accrual process and addressing misconcep-
tions. The availability and quality of information is an im-
portant factor influencing recruitment [2]. Patients have
refused to join trials for not understanding randomisation
or for fear of being a “guinea pig” [30].
Place
Place is where and when the interaction with the trial’s
product/service occurs and convenience is key [31].
From the trial’s perspective, place includes the distribution
channel through which the trial’s product/service becomes
available to the participant, which can involve the collabor-
ation of interdependent organisations and middlemen [22],
like hospitals or specialised centres. Participants’ preference
for certain environments (for example, university hospitals
over general hospitals), can affect trial participation [32].
People
To varying degrees, trials have a people-led service compo-
nent. Participants come in contact with staff such as clini-
cians, nurses, and assistants. The selection, training, and
motivation of these “trial representatives” will impact upon
recruitment. Through their empathy, competence, and
courteous manner, the trial’s people shape expectations
about the experience and the perceived quality of the offer-
ing. They play a central role in building trust and commit-
ment between the trial and its participants, to such an
extent that some trials have reported participants joining
because they were impressed with the recruiter [33]. Partic-
ipants who come to trust staff perceive lower risks to par-
ticipation [34], and communication between the physician
and the participant eases concerns about treatment “costs”
and influences trial accrual [35-37].
Physical environment
The physical environment within which a trial is deliv-
ered provides participants with cues and assurances
about its trustworthiness and scientific integrity. Partici-
pants will have greater confidence in a trial conducted in
a well-cared for facility.
Process
Processes are the actions required of participants to par-
ticipate in the trial. Here, ease of use is a key factor. For
example, the nature of the consent process can be a rea-
son for participants refusing to participate [2]. Trial
protocols can be problematic if the regimen is difficult
to follow, tedious [38], or deemed excessive [27].
Marketing research methods: researching the
marketing mix (7 Ps)
While marketing information is needed across the 7 Ps to
understand why a trial might be underperforming, some
clinical trials face specific challenges: budget limitations
and the lack of marketing expertise impose constraints.
Nevertheless, research need not be overcomplicated nor
expensive and can be conducted in informal but effective
ways [39]. Secondary data research, primary qualitative
(causal observation, personal interviews, and focus groups),
primary quantitative (i.e., questionnaires), and nested
controlled trials to empirically test the validity of diffe-
rent marketing material or interventions are all possible
research techniques [13,22,38,39].
TASK 3 – performance evaluation
A trial must monitor and evaluate its performance to in-
crease the probability that its objectives will be met. Re-
cruitment should be tracked on an on-going basis and
evaluated against goals [22], and the measures used
should generate data on the cost effectiveness of market-
ing interventions. Findings must result in learning for
the next campaign and provide input into future deci-
sions [40]. Typical indicators for a trial would include:
volume and cost per registration, consent, and random-
isation, according to media and advert/intervention type.
TASK 4 – implementing change
Having identified where problems lie and how these might
be resolved, change initiatives can occur on two levels: at
the level of single interventions and on a broader strategic
level.
At the level of single intervention, change initiatives
could include new or corrective measures to be under-
taken within a trial’s marketing mix. These could improve
promotion or communication by increasing the persua-
siveness of trial messages, or stakeholders’ awareness and
appreciation of the product benefits as well as their unde-
rstanding of trial processes. In addition, it could be desi-
rable to strive to improve participants’/collaborators’ trial
experiences by addressing shortcomings in the place,
people, physical environment, and process components of
the marketing mix and by alleviating or compensating for
the costs of trial participation/collaboration.
Broader strategic change could involve adopting a holis-
tic view to improving recruitment by choosing the optimal
mix of interventions and best strategic approachb, i.e.,
which interventions are worth introducing, modifying, or
abandoning for the most productive use of resources. It is
wise for such decisions to be made on the basis of market-
ing performance data, the expected cost effectiveness of
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the changes, as well as factors related to the trial’s re-
sources, capabilities, and priorities.
The txt2stop experience through the lens of the
recruitment optimisation model
We have presented the recruitment optimisation model’s
marketing concepts and processes, and now we will ex-
plain the txt2stop experience using the model’s frame-
work. Our purpose is to illustrate how the model can be
applied as a conceptual framework for guiding a flow of
improvements to recruitment practices. We acknow-
ledge that the model is being applied retrospectively.
Recruitment phase monitoring
Eight months into recruitment (October 2007 to June
2008) and the trial was 250 participants short of target;
4,950 subjects were still to be recruited. Yet, 937 people
had expressed an interest in the trial but had not yet
registered (i.e., had completed phase 1 without further
progression). A further 1,302 smokers had registered but
had not given or had refused to give their consent, they
had completed phase 2 with no further progression.
Only 33% of eligible participants were consenting. Inter-
ventions were needed across all phases in order to get
more people to express an interest and, crucially, to in-
crease the probability that larger percentages of those
expressing an interest would register and consent.
Marketing research and findings
Below, we summarise the main lessons learnt from the
marketing research under each of the 7 Ps and describe
the changes that followed. We do this in a table format
in the interest of brevity and clarity (Table 3).
Performance evaluation
On registration, participants were asked where they had
heard of txt2stop. A record was kept of the promotional
expenditure pertaining to each communication cam-
paign. Recruitment was monitored across sources (radio,
newspaper, GP surgeries, pharmacies, smoking cessation
clinic), within sources (e.g., different radio stations,
newspapers, or GP surgeries), and according to advert
type, where applicable. Discrepancies were noted in per-
formance in terms of volume and cost per randomisa-
tion. This resulted in strategy level modifications, as
funds were pulled from underperforming media and
campaigns, and reallocated. Poorly performing media,
such as the Internet banner and social media, were im-
mediately dropped. Instead, the very high volume of en-
quiries generated by radio, coupled with its relative cost
effectiveness and quick turnaround, made radio advertis-
ing the priority medium, and the intensity and frequency
of radio campaigns was increased. The most cost effect-
ive radio stations and advert type were identified and
reemployed as necessary. While, on average, the news-
paper adverts were more cost effective than the radio
(largely due to the free adverts in some newspapers), the
comparatively low volume of randomisations generated,
coupled with the unpredictable variability in cost per
randomisation according to newspaper type meant only
the most productive and the free adverts were kept
running.
Recruitment results
Combined, the changes resulted in substantial improve-
ments in recruitment. Most of the discussed interven-
tion level changes (across the 7 Ps) were implemented in
May/June 2008. Between July and September 2008, radio
and newspaper advertisements ceased and the relatively
modest but almost immediate increase in recruitment of
510 participants that can be observed (Figure 4) is pri-
marily attributable to recruitment via word of mouth
and to interventions introduced to increase consent and
registration rates among participants who had already
expressed an interest but had not yet registered and/or
consented (stuck in step 1 or 2 of phase 2); results from
nested control trials that we ran support this. Testimo-
nial text messages sent to participants who had regis-
tered but not consented proved effective as did the
scarcity messages [47] and sending £5 with the study
consent letter [46]. Text messages sent to potential par-
ticipants, reminding them of the option of online regis-
tration, increased registrations [46]. Following the
completion of the nested trials, the tested interventions
became standard recruitment procedures. Subsequently,
a revised radio and newspaper promotional campaign
was developed for January 2009, drawing on the experi-
ence gained in identifying effective adverts and media.
This was run in the New Year to coincide with smokers
making new year’s resolutions to quit and coupled with
the effect of the other downstream changes already dis-
cussed, the campaign resulted in the dramatic increase
in recruitment that can be observed from January 2009
until August 2009. Over the final 10 months of recruit-
ment, recruitment levels more than quadrupled, the
average cost per person randomised fell to a 1/3 over
the last two quarters, and the proportion of eligible par-
ticipants joining the trial rose from 33% to 57%, exceed-
ing the 50% target. The trial finished by recruiting four
months ahead of schedule.
Figure 5 shows the number of participants recruited
according to source, before and after the implemented
changes. Meaningful improvements in the recruitment
performance of newspaper adverts, GPs, and in the
“word of mouth” media can be noted. The latter is testa-
ment to participants having a positive experience of the
trial. However, recruitment was largely through radio
adverts.
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Discussion
Summary of the recruitment optimisation model
The model is circular and thus learning can begin at any
stage. At its heart lie three interdependent processes: re-
cruitment phase monitoring, marketing research, and
performance evaluation. Recruitment phase tracking locates
bottlenecks in the recruitment process while marketing
research provides insights into the nature of the problems
and how these can be overcome. Performance evaluation
allows trialists to determine the efficacy and cost effective-
ness of a trial’s marketing interventions and strategies and
to allocate resources accordingly. These three processes
provide the knowledge for making improvements to
existing interventions/strategies and for introducing
Table 3 The 7 Ps lessons learned and changes made
The 7 Ps Lessons learned and changes made
Product EH reviewed the clinical trials and smoking cessation literature using the MEDLINE database and key search terms
“recruitment and trials”, “smoking cessation”, and years 1960 to 2007. A range of reasons for participating in trials was
identified from the literature.
General core benefits: The opportunity to receive an intervention not otherwise available and the satisfaction of
contributing to research [33,41]. Trial specific core benefits: The prospects of saving money, of improved health, of
wanting to avoid damage to an unborn baby, and of quitting for one’s loved ones.
Price (cost) Insights from social psychology theories were used to influence potential participants’ perceptions of the psychological
costs to (non) participation [42].
Social validation theory: Knowing that others similar to oneself have joined can provide reassurance that joining is the
right decision [43].
Norms of reciprocity: Receiving small financial and other incentives can increase participants’ willingness to cooperate [44].
Theory of scarcity: Scarcity can act a heuristic for the perceived value of a medical intervention [45].
£5 was sent to prospective participants with their covering letter to induce norms of reciprocity and to dismiss concerns that the
trial could be a scam (i.e., charge for text messages received) [46]. Text messages were sent to participants who had registered and
were eligible to join, to remind them that they could consent and that only 300 places were left
(as was the case at the time) [47].
To smokers
Promotion
communication
Theories of persuasion suggest testimonials can generate positive responses [28,48]. Qualitative feedback from participants about
their experience with txt2stop was obtained and with permission used in text messages sent to potential participants who had
received the trial information but had not yet consented.
The study information was personalised, shortened, and simplified, as the literature on trial participation suggested people might be
more responsive to such types of communication [2,35,49]. The content was amended to mention the product tangible and general
core benefits, that trial participation offered the possibility of trying a free and novel service, and that the research could be used by
the NHS [50]. To signal trustworthiness all correspondence included university logos and was personally signed [3,29,36].
New newspaper advertisements were prepared to increase public interest. These promoted the benefits to quitting (product
core benefits) and used testimonials to maximise the impact of the message. Previous advertisements merely made people aware
of txt2stop.
To health care providers
Smoking cessation literature suggested health care professionals can act as important triggers for quit attempts [51]. Yet, very few
participants had been recruited through health care providers. GPs interviewed reported that remembering and workload were
issues, so recruitment through GP surgeries was redesigned. GPs were reimbursed via the PCRN for admin staff writing to smokers
on their lists inviting them to take part in the trial. Pharmacists reported wanting paying for recruitment but at the time there was
no mechanism for funding this. Smoking cessation services received funds for smokers they helped to quit and so they had no
incentive to refer smokers on. No further effort was put into promotions through these channels. However, a txt2stop link was
placed on the NHS smoking cessation websites.
Place Not applicable to txt2stop, interaction occurred over the phone.
People Adequately managing “moments of truth” in the participant/staff interaction, such as responding convincingly to a challenging
query, and minimising “response rate tyranny” (annoyance and harassment) is key to engaging potential participants [9,52].
Through informal observations and through semi-structured phone interviews held with a sample of individuals who had refused
consent, participants’ concerns and misconceptions that were unique to txt2stop were spotted. Staff received training to address
concerns such as that DNA testing was secretly linked to the provision of a saliva sample. Staff also received training on how to
deal with awkward and busy participants and on how to show empathy towards those who were allocated to the control group
while reminding them they still had an important role to play in the trial. Capitalising on the good rapport that phone staff had
with participants, staff asked participants to promote the trial by word of mouth.
Physical
environment
Not applicable to txt2stop, interaction occurred over the phone.
Process Online registration (instead of just by phone) was made available for busy and hard to reach individuals and promoted in the
voice messages left on their mobiles and also by a series of text messages.
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new bespoke solutions. The changes will shape the tar-
get market’s perception and awareness of the trial,
their evaluation of costs and benefits, and the extent to
which their needs are satisfied. The effects will be reflected
in recruitment outcome measures (volume of randomi-
sations, cost per randomisation, registration and con-
sent rates) generating new sets of (monthly) data, which
can feed back into the system, forming the basis of a
new learning cycle (Figure 3).
Comparison with existing literature
The clinical trials literature has struggled to identify the
factors and practices responsible for successful recruit-
ment. Quantitative approaches that have used broad data
sets have encountered difficulties in reaching synthesis,
with comparative analysis producing little insight due to
the complexity and marked variability of the trials under
consideration [1,5,53]. Qualitative studies have provided
more detailed descriptive accounts but given the context
specificity of many trials, the scope for a direct transfer of
lessons learned to other trials can be limited [17,54,55].
Both approaches have been hampered by the lack of a
conceptual framework to assist with sense making. There
is a recognised and urgent need for models that provide
relevant material for those undertaking clinical trials [7].
Francis et al. [9] (Figure 6) proposed a reference model
for marketing a trial which has served as a tentative diag-
nostic tool [56]. We argue the model is most valuable as a
reference tool rather than as a dynamic diagnostic tool.
While the Francis model suggests domains in which trial
management needs to form marketing strategies, it does
not pinpoint the core practices needed to support learn-
ing. What is called for is a model that recognises the task
of improving recruitment as an emergent process where
any deviations from expectations or plans can be spotted
and analysed, and remedial action can be undertaken. The
Figure 4 Trial recruitment target vs. actual.
Figure 5 Number of participants recruited according to source.
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recruitment optimisation model aims to fill this gap. The
importance of this is illustrated by the txt2stop trial, which
fully recruited to its pilot trial within two weeks; thus, the
poor initial recruitment to the main trial was unexpected.
Study limitations and subsequent areas for future research
Although firmly grounded in marketing theory and the
clinical trials literature, the recruitment optimisation model
is founded on a post hoc analysis of a single case study
(txt2stop) and it was not feasible to quantify the pre-
cise extent to which the learning processes enacted
were responsible for all the improvements in recruit-
ment described. The model is best viewed as a tenta-
tive framework to be tested and validated by other
types of trials.
The literature searches completed by EH were done
within the budget and time constraints of a trial seeking
solutions to trial recruitment and did not meet the stan-
dards of a systematic review of evidence. Only one data-
base (Medline) was searched and a more exhaustive search
strategy would be likely to have resulted in the identifica-
tion of further relevant studies. However, systematic re-
views of the relevant trial participation literature have since
been completed [26,57].
Conclusions
Improving recruitment performance requires a learning
process. The recruitment optimisation model suggests
the key practices (marketing research, monitoring and
evaluating performance) and marketing constructs (the 7
Ps) that are necessary to guide the learning experience.
The 7 Ps provide a format within which learning can
occur. Therefore, the main contributions of this paper
are to advance the clinical trial literature’s understanding
of i) what trialists need to learn about, ii) what helps
them learn better, and iii) how learning can translate
into improved action and increased recruitment. There
are potentially significant implications for clinical trials
and funding bodies. The model’s application could opti-
mise or help improve the recruitment of clinical studies
resulting in more efficient trials.
End notes
aFor mode we refer to the distinction that can be drawn
between the two different ways of gaining knowledge,
the paradigmatic and the narrative, and in particular we
draw attention to the merits of narrative communica-
tion. See Hinyard & Kreuter, [28].
bFor strategy we refer to broad decisions relating to a
trial’s recruitment process, for instance whether to re-
cruit using mass media tools for promotion or in-person
approaches. Strategies themselves consist of individual
interventions, which determine how a strategy is exe-
cuted. Interventions can include anything from the use
of posters to participant letters, radio adverts, or the use
of intermediaries (GPs).
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